The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The company’s Growth Portfolio delivered $6.2 billion in revenue
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The company posted revenue of Rs. 703 crore in Q4 FY26
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Rs. 40 cr buyback, 200% dividend announced
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
The deal signals a clear push to expand access to care in underserved regions
Acquires 85% stake in the formulations company valued at Rs 200 crore enterprise value; founder Vivek Seth to retain 15%
Subscribe To Our Newsletter & Stay Updated
